Home Data Calendar Blog

BBIO

Tables

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Common Stock Value 0.16 0.15 0.15 0.15 0.15 0.15 0.15 0.12 0.12 0.12 0.12

Weighted Average Number Of Diluted Shares Outstanding 147.94 146.68 NA NA 146.66 146.75 NA NA NA NA NA

Weighted Average Number Of Shares Outstanding Basic 147.94 146.68 NA NA 146.66 146.75 NA NA NA NA NA

Weighted Average Number Of Share Outstanding Basic And Diluted NA NA 145.88 NA 146.66 146.75 138.63 NA 118.17 NA 117.07

Earnings Per Share Basic -0.93 -0.07 NA NA -1.06 -0.66 NA NA NA NA NA

Earnings Per Share Diluted -0.93 -0.07 NA NA -1.06 -0.66 NA NA NA NA NA

Earnings Per Share Basic And Diluted NA NA -1.35 -1.02 -1.06 -0.66 -1.18 -1.01 -0.98 -0.62 -0.51

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Common Stock Value	0.16	0.15	0.15	0.15	0.15	0.15	0.15	0.12	0.12	0.12	0.12
Weighted Average Number Of Diluted Shares Outstanding	147.94	146.68	NA	NA	146.66	146.75	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic	147.94	146.68	NA	NA	146.66	146.75	NA	NA	NA	NA	NA
Weighted Average Number Of Share Outstanding Basic And Diluted	NA	NA	145.88	NA	146.66	146.75	138.63	NA	118.17	NA	117.07
Earnings Per Share Basic	-0.93	-0.07	NA	NA	-1.06	-0.66	NA	NA	NA	NA	NA
Earnings Per Share Diluted	-0.93	-0.07	NA	NA	-1.06	-0.66	NA	NA	NA	NA	NA
Earnings Per Share Basic And Diluted	NA	NA	-1.35	-1.02	-1.06	-0.66	-1.18	-1.01	-0.98	-0.62	-0.51

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Revenue From Contract With Customer Excluding Assessed Tax 0.34 73.75 1.69 12.89 2.34 54.02 0.46 0.12 8.13 13.82 26.74

Revenues 0.34 73.75 1.69 12.89 2.34 54.02 0.46 0.12 8.13 13.82 26.74

Costs And Expenses 129.45 153.92 175.37 178.50 151.84 148.04 167.97 127.61 128.07 NA NA

Research And Development Expense 92.51 108.40 107.65 122.20 104.31 101.96 122.56 90.17 92.05 57.48 55.28

Selling General And Administrative Expense 31.19 36.43 43.71 54.75 46.08 45.97 45.41 37.44 36.02 NA NA

Operating Income Loss -129.12 -80.18 -173.68 -165.61 -149.50 -94.02 -167.50 -127.49 -119.94 -78.64 -54.53

Interest Expense 19.82 20.28 20.34 15.13 11.07 10.84 9.74 10.96 10.93 3.04 2.11

Interest Expense Debt 8.54 8.53 8.53 8.52 8.51 8.51 7.10 NA 8.21 NA NA

Interest Paid Net 22.14 6.63 18.81 1.53 17.43 1.90 8.91 2.04 9.16 1.76 1.75

Allocated Share Based Compensation Expense 18.66 28.30 24.28 22.51 16.13 32.03 34.90 12.15 17.70 10.01 5.78

Profit Loss -140.19 -2.56 -201.33 -152.28 -161.02 -102.07 -171.08 -135.03 -130.17 -84.15 -60.66

Comprehensive Income Net Of Tax -137.26 -9.90 -196.65 -147.33 -155.95 -96.25 -163.33 -120.25 -116.26 -56.05 -60.51

Net Income Loss Available To Common Stockholders Basic -137.34 -9.86 -196.40 -147.18 -155.94 -96.35 -163.08 -119.98 -115.86 -73.46 -59.98

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Revenue From Contract With Customer Excluding Assessed Tax	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Revenues	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Costs And Expenses	129.45	153.92	175.37	178.50	151.84	148.04	167.97	127.61	128.07	NA	NA
Research And Development Expense	92.51	108.40	107.65	122.20	104.31	101.96	122.56	90.17	92.05	57.48	55.28
Selling General And Administrative Expense	31.19	36.43	43.71	54.75	46.08	45.97	45.41	37.44	36.02	NA	NA
Operating Income Loss	-129.12	-80.18	-173.68	-165.61	-149.50	-94.02	-167.50	-127.49	-119.94	-78.64	-54.53
Interest Expense	19.82	20.28	20.34	15.13	11.07	10.84	9.74	10.96	10.93	3.04	2.11
Interest Expense Debt	8.54	8.53	8.53	8.52	8.51	8.51	7.10	NA	8.21	NA	NA
Interest Paid Net	22.14	6.63	18.81	1.53	17.43	1.90	8.91	2.04	9.16	1.76	1.75
Allocated Share Based Compensation Expense	18.66	28.30	24.28	22.51	16.13	32.03	34.90	12.15	17.70	10.01	5.78
Profit Loss	-140.19	-2.56	-201.33	-152.28	-161.02	-102.07	-171.08	-135.03	-130.17	-84.15	-60.66
Comprehensive Income Net Of Tax	-137.26	-9.90	-196.65	-147.33	-155.95	-96.25	-163.33	-120.25	-116.26	-56.05	-60.51
Net Income Loss Available To Common Stockholders Basic	-137.34	-9.86	-196.40	-147.18	-155.94	-96.35	-163.08	-119.98	-115.86	-73.46	-59.98

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Assets 728.74 862.23 813.15 1012.79 781.52 1081.49 1093.31 703.59 787.69 631.68 640.53

Liabilities 1859.11 1877.25 1853.84 1878.37 1517.40 1537.11 1481.40 595.70 569.31 155.70 116.26

Liabilities And Stockholders Equity 728.74 862.23 813.15 1012.79 781.52 1081.49 1093.31 703.59 787.69 631.68 640.53

Stockholders Equity -1138.42 -1025.53 -1041.00 -870.41 -743.40 -464.29 -395.29 57.91 163.76 408.45 459.76

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Assets	728.74	862.23	813.15	1012.79	781.52	1081.49	1093.31	703.59	787.69	631.68	640.53
Liabilities	1859.11	1877.25	1853.84	1878.37	1517.40	1537.11	1481.40	595.70	569.31	155.70	116.26
Liabilities And Stockholders Equity	728.74	862.23	813.15	1012.79	781.52	1081.49	1093.31	703.59	787.69	631.68	640.53
Stockholders Equity	-1138.42	-1025.53	-1041.00	-870.41	-743.40	-464.29	-395.29	57.91	163.76	408.45	459.76

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Assets Current 642.22 771.28 716.23 888.86 639.71 909.87 945.11 642.82 745.38 568.62 558.15

Cash And Cash Equivalents At Carrying Value 483.24 470.10 371.55 393.77 180.35 378.42 471.18 356.08 366.97 363.77 413.97

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 485.79 472.65 374.19 NA 183.08 381.13 473.77 NA NA NA NA

Marketable Securities Current 75.08 218.47 261.90 393.74 419.26 459.24 447.94 251.01 343.71 182.22 NA

Prepaid Expense And Other Assets Current 25.66 32.75 34.02 32.45 31.93 26.67 25.53 35.73 26.70 22.63 22.10

Equity Securities Fv Ni 33.66 27.14 37.77 49.15 NA NA NA NA NA NA NA

Available For Sale Securities Debt Securities 525.67 475.76 520.31 626.84 488.91 775.59 863.27 517.45 609.39 521.10 554.55

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Assets Current	642.22	771.28	716.23	888.86	639.71	909.87	945.11	642.82	745.38	568.62	558.15
Cash And Cash Equivalents At Carrying Value	483.24	470.10	371.55	393.77	180.35	378.42	471.18	356.08	366.97	363.77	413.97
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	485.79	472.65	374.19	NA	183.08	381.13	473.77	NA	NA	NA	NA
Marketable Securities Current	75.08	218.47	261.90	393.74	419.26	459.24	447.94	251.01	343.71	182.22	NA
Prepaid Expense And Other Assets Current	25.66	32.75	34.02	32.45	31.93	26.67	25.53	35.73	26.70	22.63	22.10
Equity Securities Fv Ni	33.66	27.14	37.77	49.15	NA	NA	NA	NA	NA	NA	NA
Available For Sale Securities Debt Securities	525.67	475.76	520.31	626.84	488.91	775.59	863.27	517.45	609.39	521.10	554.55

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Amortization Of Intangible Assets 0.60 0.60 0.90 1.30 0.70 NA NA NA NA NA NA

Property Plant And Equipment Net 15.60 16.87 17.18 30.07 27.74 26.27 22.82 20.32 16.18 5.62 2.98

Intangible Assets Net Excluding Goodwill 29.31 29.91 30.48 44.93 46.20 NA NA NA NA NA NA

Finite Lived Intangible Assets Net 29.31 29.91 30.48 44.93 46.20 NA NA NA NA NA NA

Other Assets Noncurrent 29.87 31.32 35.33 33.03 33.05 49.80 30.18 23.93 16.48 26.29 2.60

Equity Securities Fv Ni 33.66 27.14 37.77 49.15 NA NA NA NA NA NA NA

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Amortization Of Intangible Assets	0.60	0.60	0.90	1.30	0.70	NA	NA	NA	NA	NA	NA
Property Plant And Equipment Net	15.60	16.87	17.18	30.07	27.74	26.27	22.82	20.32	16.18	5.62	2.98
Intangible Assets Net Excluding Goodwill	29.31	29.91	30.48	44.93	46.20	NA	NA	NA	NA	NA	NA
Finite Lived Intangible Assets Net	29.31	29.91	30.48	44.93	46.20	NA	NA	NA	NA	NA	NA
Other Assets Noncurrent	29.87	31.32	35.33	33.03	33.05	49.80	30.18	23.93	16.48	26.29	2.60
Equity Securities Fv Ni	33.66	27.14	37.77	49.15	NA	NA	NA	NA	NA	NA	NA

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Liabilities Current 119.19 141.16 103.46 135.07 95.82 131.91 94.73 95.65 75.71 60.38 39.86

Accounts Payable Current 10.16 8.79 10.11 11.88 12.04 22.33 10.34 8.95 9.84 8.85 10.27

Other Accrued Liabilities Current 23.84 31.98 24.78 30.28 14.61 21.18 18.25 13.35 NA 3.02 3.22

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Liabilities Current	119.19	141.16	103.46	135.07	95.82	131.91	94.73	95.65	75.71	60.38	39.86
Accounts Payable Current	10.16	8.79	10.11	11.88	12.04	22.33	10.34	8.95	9.84	8.85	10.27
Other Accrued Liabilities Current	23.84	31.98	24.78	30.28	14.61	21.18	18.25	13.35	NA	3.02	3.22

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Long Term Debt Noncurrent NA NA 434.11 430.75 103.14 102.61 90.76 92.42 93.39 91.79 75.02

Minority Interest 10.43 12.02 -0.03 3.41 4.56 6.80 5.93 48.35 52.06 65.28 61.94

Other Liabilities Noncurrent 28.23 28.63 26.83 22.07 27.58 13.27 11.61 9.52 13.47 3.53 1.39

Operating Lease Liability Noncurrent 13.00 14.28 15.49 17.43 18.68 18.02 13.86 14.68 8.24 NA NA

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Long Term Debt Noncurrent	NA	NA	434.11	430.75	103.14	102.61	90.76	92.42	93.39	91.79	75.02
Minority Interest	10.43	12.02	-0.03	3.41	4.56	6.80	5.93	48.35	52.06	65.28	61.94
Other Liabilities Noncurrent	28.23	28.63	26.83	22.07	27.58	13.27	11.61	9.52	13.47	3.53	1.39
Operating Lease Liability Noncurrent	13.00	14.28	15.49	17.43	18.68	18.02	13.86	14.68	8.24	NA	NA

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Stockholders Equity -1138.42 -1025.53 -1041.00 -870.41 -743.40 -464.29 -395.29 57.91 163.76 408.45 459.76

Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1127.98 -1013.51 -1041.02 -867.00 -738.84 -457.49 -389.37 106.26 215.81 473.73 521.70

Common Stock Value 0.16 0.15 0.15 0.15 0.15 0.15 0.15 0.12 0.12 0.12 0.12

Additional Paid In Capital Common Stock 917.33 892.96 867.60 841.53 821.22 799.68 767.12 1021.34 1006.94 848.11 826.06

Retained Earnings Accumulated Deficit -1780.56 -1643.22 -1633.36 -1436.97 -1289.79 -1133.85 -1037.51 -888.75 -768.77 -440.03 -366.57

Accumulated Other Comprehensive Income Loss Net Of Tax -0.35 -0.43 -0.38 -0.13 0.02 0.04 -0.06 0.19 0.46 0.25 NA

Treasury Stock Value 275.00 275.00 275.00 275.00 275.00 130.31 125.00 75.00 NA NA NA

Minority Interest 10.43 12.02 -0.03 3.41 4.56 6.80 5.93 48.35 52.06 65.28 61.94

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 23.23 23.90 25.42 NA 16.90 32.51 19.84 NA 11.75 NA NA

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Stockholders Equity	-1138.42	-1025.53	-1041.00	-870.41	-743.40	-464.29	-395.29	57.91	163.76	408.45	459.76
Stockholders Equity Including Portion Attributable To Noncontrolling Interest	-1127.98	-1013.51	-1041.02	-867.00	-738.84	-457.49	-389.37	106.26	215.81	473.73	521.70
Common Stock Value	0.16	0.15	0.15	0.15	0.15	0.15	0.15	0.12	0.12	0.12	0.12
Additional Paid In Capital Common Stock	917.33	892.96	867.60	841.53	821.22	799.68	767.12	1021.34	1006.94	848.11	826.06
Retained Earnings Accumulated Deficit	-1780.56	-1643.22	-1633.36	-1436.97	-1289.79	-1133.85	-1037.51	-888.75	-768.77	-440.03	-366.57
Accumulated Other Comprehensive Income Loss Net Of Tax	-0.35	-0.43	-0.38	-0.13	0.02	0.04	-0.06	0.19	0.46	0.25	NA
Treasury Stock Value	275.00	275.00	275.00	275.00	275.00	130.31	125.00	75.00	NA	NA	NA
Minority Interest	10.43	12.02	-0.03	3.41	4.56	6.80	5.93	48.35	52.06	65.28	61.94
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value	23.23	23.90	25.42	NA	16.90	32.51	19.84	NA	11.75	NA	NA

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Net Cash Provided By Used In Operating Activities -135.16 -30.45 -160.63 -133.90 -121.56 -91.71 -150.76 -96.26 -131.68 -76.20 -50.00

Net Cash Provided By Used In Investing Activities 146.86 149.70 138.62 21.80 58.97 0.46 -282.05 83.02 -45.05 -16.90 -197.34

Net Cash Provided By Used In Financing Activities 1.45 -20.80 -0.16 325.38 -135.46 -1.39 547.91 4.53 2.78 42.90 367.51

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Operating Activities	-135.16	-30.45	-160.63	-133.90	-121.56	-91.71	-150.76	-96.26	-131.68	-76.20	-50.00
Net Cash Provided By Used In Investing Activities	146.86	149.70	138.62	21.80	58.97	0.46	-282.05	83.02	-45.05	-16.90	-197.34
Net Cash Provided By Used In Financing Activities	1.45	-20.80	-0.16	325.38	-135.46	-1.39	547.91	4.53	2.78	42.90	367.51

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Net Cash Provided By Used In Operating Activities -135.16 -30.45 -160.63 -133.90 -121.56 -91.71 -150.76 -96.26 -131.68 -76.20 -50.00

Profit Loss -140.19 -2.56 -201.33 -152.28 -161.02 -102.07 -171.08 -135.03 -130.17 -84.15 -60.66

Depreciation Depletion And Amortization 1.65 1.58 1.88 1.53 0.27 3.49 0.57 0.43 -1.01 NA NA

Increase Decrease In Accounts Payable 1.36 -1.28 -1.81 1.47 -11.66 11.23 1.79 -1.28 -3.44 -1.42 -3.38

Share Based Compensation 17.36 28.29 24.12 19.77 16.04 30.11 33.58 12.15 17.70 10.01 5.78

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Operating Activities	-135.16	-30.45	-160.63	-133.90	-121.56	-91.71	-150.76	-96.26	-131.68	-76.20	-50.00
Profit Loss	-140.19	-2.56	-201.33	-152.28	-161.02	-102.07	-171.08	-135.03	-130.17	-84.15	-60.66
Depreciation Depletion And Amortization	1.65	1.58	1.88	1.53	0.27	3.49	0.57	0.43	-1.01	NA	NA
Increase Decrease In Accounts Payable	1.36	-1.28	-1.81	1.47	-11.66	11.23	1.79	-1.28	-3.44	-1.42	-3.38
Share Based Compensation	17.36	28.29	24.12	19.77	16.04	30.11	33.58	12.15	17.70	10.01	5.78

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Net Cash Provided By Used In Investing Activities 146.86 149.70 138.62 21.80 58.97 0.46 -282.05 83.02 -45.05 -16.90 -197.34

Payments To Acquire Property Plant And Equipment 0.76 2.40 0.86 2.54 6.46 2.29 1.96 2.15 0.55 1.75 0.38

		2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Investing Activities		146.86	149.70	138.62	21.80	58.97	0.46	-282.05	83.02	-45.05	-16.90	-197.34
Payments To Acquire Property Plant And Equipment		0.76	2.40	0.86	2.54	6.46	2.29	1.96	2.15	0.55	1.75	0.38

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Net Cash Provided By Used In Financing Activities 1.45 -20.80 -0.16 325.38 -135.46 -1.39 547.91 4.53 2.78 42.90 367.51

		2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Financing Activities		1.45	-20.80	-0.16	325.38	-135.46	-1.39	547.91	4.53	2.78	42.90	367.51

2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30

Revenues 0.34 73.75 1.69 12.89 2.34 54.02 0.46 0.12 8.13 13.82 26.74

Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement -0.10 3.20 NA NA NA NA NA NA NA NA NA

Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement -0.10 73.40 NA NA NA NA NA NA NA NA NA

Lian Bio, License, License Agreement 0.30 NA NA 0.00 0.00 8.50 NA NA NA NA NA

License NA NA 0.23 10.84 1.58 53.04 0.46 -0.13 8.00 NA NA

License And Service 0.34 73.75 NA NA 1.58 53.04 NA NA NA NA NA

Product 0.00 0.00 1.46 2.05 0.76 0.99 NA NA NA NA NA

Revenue From Contract With Customer Excluding Assessed Tax 0.34 73.75 1.69 12.89 2.34 54.02 0.46 0.12 8.13 13.82 26.74

Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement -0.10 3.20 NA NA NA NA NA NA NA NA NA

Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement -0.10 73.40 NA NA NA NA NA NA NA NA NA

Lian Bio, License, License Agreement 0.30 NA NA 0.00 0.00 8.50 NA NA NA NA NA

License NA NA 0.23 10.84 1.58 53.04 0.46 -0.13 8.00 NA NA

License And Service 0.34 73.75 NA NA 1.58 53.04 NA NA NA NA NA

Product 0.00 0.00 1.46 2.05 0.76 0.99 NA NA NA NA NA

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Revenues	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement	-0.10	3.20	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement	-0.10	73.40	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, License, License Agreement	0.30	NA	NA	0.00	0.00	8.50	NA	NA	NA	NA	NA
License	NA	NA	0.23	10.84	1.58	53.04	0.46	-0.13	8.00	NA	NA
License And Service	0.34	73.75	NA	NA	1.58	53.04	NA	NA	NA	NA	NA
Product	0.00	0.00	1.46	2.05	0.76	0.99	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement	-0.10	3.20	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement	-0.10	73.40	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, License, License Agreement	0.30	NA	NA	0.00	0.00	8.50	NA	NA	NA	NA	NA
License	NA	NA	0.23	10.84	1.58	53.04	0.46	-0.13	8.00	NA	NA
License And Service	0.34	73.75	NA	NA	1.58	53.04	NA	NA	NA	NA	NA
Product	0.00	0.00	1.46	2.05	0.76	0.99	NA	NA	NA	NA	NA

Plots across concepts

IncomeStatement

Balance Sheet

Assets

Current Assets

NonCurrent Assets

Liabilities

Current Liabilities

Noncurrent Liabilities

Stockholders Equity

CashFlow

NetCashProvidedByUsedInOperatingActivities

NetCashProvidedByUsedInInvestingActivities

NetCashProvidedByUsedInFinancingActivities

OperatingLeaseLiability

NonoperatingIncomeExpense

LesseeOperatingLeaseLiabilityPaymentsDue

FiniteLivedIntangibleAssets

Line plots across dimensions of each concept

TTM Greenblatt ROC
_
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)

us-gaap:Revenues
us-gaap:ProductOrService
(None,)

us-gaap:InterestExpenseDebt
us-gaap:DebtInstrument
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities, us-gaap:IncomeStatementLocation
('bbio:BridgeBioServicesInc', None)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:PlanName
(None, 'bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan')

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
(None, 'us-gaap:ShortTermInvestments')

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents
(None,)